613-85-4Relevant articles and documents
Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid
Maclean, Mark A.,Diez-Cecilia, Elena,Lavery, Christopher B.,Reed, Mark A.,Wang, Yanfei,Weaver, Donald F.,Stradiotto, Mark
supporting information, p. 100 - 104 (2015/12/18)
N-Aryl derivatives of edaravone were identified as potentially effective small molecule inhibitors of tau and beta-amyloid aggregation in the context of developing disease-modifying therapeutics for Alzheimer's disease (AD). Palladium-catalyzed hydrazine monoarylation protocols were then employed as an expedient means of preparing a focused library of 21 edaravone derivatives featuring varied N-aryl substitution, thereby enabling structure-activity relationship (SAR) studies. On the basis of data obtained from two functional biochemical assays examining the effect of edaravone derivatives on both fibril and oligomer formation, it was determined that derivatives featuring an N-biaryl motif were four-fold more potent than edaravone.
Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities
-
Page/Page column 20, (2008/06/13)
The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5). R1. R2=H. —CH3, —CH(CH3)2, —OCH3, —Cl.—CF3,—OCF3,—SCH3, R3=an amino acid group which may be hydrolysed by a carboxypeptidase A and R4=a basic amino acid group.